Abstract
α-Synuclein forms amyloid deposits in the dopaminergic neurons; a process that is believed to contribute to the Parkinson’s disease. An emerging theme in amyloid research is the hypothesis that the toxic species produced during amyloid formation share common physic-chemical features and exert their effects by common modes. This prompted the idea that molecules able to inhibit a protein aggregation process may cross-react with other amyloidogenic proteins, interfering in their fibrils formation. We investigate the ability of analogues of the heptapeptide H-Arg-Lys-Val-MePhe-Tyr-Thr-Trp- OH2, an inhibitor of Aβ-peptide aggregation, to cross-react with α-synuclein interfering with its fibril formation. The influence of the MePhe topography on the interaction with α-synuclein has also been evaluated, replacing the MePhe residue with either Phe or the conformationally restricted Tic residues. Peptides interact with good affinity with the
Keywords: α-synuclein, β-breaker peptides, conformational constraints, protein-peptide interaction.
Protein & Peptide Letters
Title:Peptides as Modulators of α-Synuclein Aggregation
Volume: 22 Issue: 4
Author(s): Paolo Ruzza, Matteo Gazziero, Maria De Marchi, Giada Massalongo, Anna Marchiani, Ida Autiero, Isabella Tessari, Luigi Bubacco and Andrea Cald
Affiliation:
Keywords: α-synuclein, β-breaker peptides, conformational constraints, protein-peptide interaction.
Abstract: α-Synuclein forms amyloid deposits in the dopaminergic neurons; a process that is believed to contribute to the Parkinson’s disease. An emerging theme in amyloid research is the hypothesis that the toxic species produced during amyloid formation share common physic-chemical features and exert their effects by common modes. This prompted the idea that molecules able to inhibit a protein aggregation process may cross-react with other amyloidogenic proteins, interfering in their fibrils formation. We investigate the ability of analogues of the heptapeptide H-Arg-Lys-Val-MePhe-Tyr-Thr-Trp- OH2, an inhibitor of Aβ-peptide aggregation, to cross-react with α-synuclein interfering with its fibril formation. The influence of the MePhe topography on the interaction with α-synuclein has also been evaluated, replacing the MePhe residue with either Phe or the conformationally restricted Tic residues. Peptides interact with good affinity with the
Export Options
About this article
Cite this article as:
Ruzza Paolo, Gazziero Matteo, De Marchi Maria, Massalongo Giada, Marchiani Anna, Autiero Ida, Tessari Isabella, Bubacco Luigi and Cald Andrea, Peptides as Modulators of α-Synuclein Aggregation, Protein & Peptide Letters 2015; 22 (4) . https://dx.doi.org/10.2174/0929866522666150209142649
DOI https://dx.doi.org/10.2174/0929866522666150209142649 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Lipid Nanoparticles for the Delivery of Active Natural Medicines
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis
Current Reviews in Clinical and Experimental Pharmacology Different Types of Cell Death in Organismal Aging and Longevity: State of the Art and Possible Systems Biology Approach
Current Pharmaceutical Design Assessment of Functional and Biological Compatibility of Antenna in a Head-Mountable DBS Device Using a Rat Model
Neuroscience and Biomedical Engineering (Discontinued) The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Commentary (Complement-Initiated Neuroinflammation and Its Role in Early Stage Alzheimers Disease)
Current Alzheimer Research Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients
Current Neurovascular Research The Effect of Potato Almond Orange Cookies on their Weight, BMI, Hemoglobin, and Lymphocyte Status of Undernourished Older People during COVID-19 Pandemic
Current Nutrition & Food Science Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
CNS & Neurological Disorders - Drug Targets Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism Imaging Biomarkers of Spine Osteoarthritis
Current Rheumatology Reviews Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Classical and Hologram QSAR Studies on a Series of Tacrine Derivatives as Butyrylcholinesterase Inhibitors
Letters in Drug Design & Discovery